Nanalysis appoints Dr. René Lenggenhager to Board of Directors

CALGARY — Nanalysis Scientific Corp. has announced that effective January 1, 2022, Dr. René Lenggenhager will join its Board of Directors.

The company stated that Dr. Lenggenhager is an experienced public company executive and board member with a successful career in global technology companies. Additionally, Dr. Lenggenhager is investing in Nanalysis via non-brokered private placement of 150,000 common shares of the Company at a price of $1.35 per share for aggregate gross proceeds of $202,500.

According to a company statement, Dr. Lenggenhager brings to Nanalysis a diverse set of experiences and capabilities over a 37 year career in advanced industrial technology. He has a background of continuously innovating technology components and systems, with a focus on high-precision measuring, testing and automation equipment. His experience includes over 20 years of management and development, with full P&L responsibility of globally active and publicly listed  technology companies including  Comet Group, Bruker BioSpin, Mettler-Toledo and Siemens Building Technologies.

Nanalysis also stated that throughout his career, Dr. Lenggenhager defined and implemented new product strategies for low-to high-field Nuclear Magnetic Resonance  products, and consolidated all service activities into one service division. Dr. Lenggenhager also deployed a global supply chain management and an outsourcing strategy.

Dr. Lenggenhager holds a PhD in physics from ETH Zurich and received an Executive MBA at the University of St. Gallen.

“There are very few people in the world that have the strategic acumen in the areas of magnetic resonance and related products, with such a positive potential to add value to our company. As all CEOs must do, I am committed to bringing talented and experienced people onboard, who are complementary to our existing team, and René is exemplary of that evolution,” said Sean Krakiwsky, founder and CEO of Nanalysis in a statement.